DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2038
INDEX
Insulin (Cont.):
as antidote, 86t
blood levels in type 2 diabetes,
1249f
continuous subcutaneous infusion
of, 1253–1254
delivery, 1253–1256
formulations, 1249t
and glucose homeostasis, 1240f
and incretins, 1271f
and plasma chylomicrons, 881
preparation, 1249t, 1250–1251
protamine-containing, 858–859
receptor signaling, 1243f
regimens, 1263f
secretagogues, 1253t, 1256–1262
secretion of, 1240–1242
regulation of, 1242f
synthesis and structure, 1241f
vs. other diabetes treatments, 1259t
Insulin-like growth factor 1 receptor
(IGF-1R), 1744, 1744f
Insulin-like growth factors (IGFs),
type 1, 1117
Insulinoma, malignant, drugs for,
1668t–1670t
Insulin receptor(s), 1242–1244
Insulin resistance, 877–878,
1246–1247
Insulin sensitizer(s), effects on
ovulation and fertility, 1845
Integrase inhibitors, 1658–1659
Integrative chemical communication,
in central nervous system,
366–371
Intellectual property, 12
Interactions, drug-drug interactions,
77–78
CYPs and, 129–130
hepatic transporters and, 110
Intercellular adhesion molecule 1
(ICAM-1), in inflammation,
960
Interferon(s), 1596t
for cutaneous viral infections, 1818
immunostimulation and, 1022
polymorphisms and response to,
160t
Interferon alfa, 1668t–1670t
pharmacokinetics of, 1851t
Interferon beta, pharmacokinetics of,
1852t
Interferon(s) (IFN), 1745
Intergenic polymorphism, 155t
Intergenic region, 148f
Interleukin(s) (IL), 1070t, 1745
IL-1
as immunosuppressive agent,
1018–1019
in inflammation, 960, 961
in rheumatoid arthritis, 961
IL-2, 1070t, 1668t–1670t,
1769–1770
immunosuppression and, 1022
Intermediate-density lipoproteins
(IDL), 878, 879t
Intermittent dosage, 36
International HapMap Project, 153t
International normalized ratio (INR),
862, 864, 865
International sensitivity index (ISI),
865
Interstitial cells of Cajal (ICCs), 175
Interval, dosing, for intermittent
dosage, 36
Intestinal secretions, eicosanoids and,
950
Intestines. See also Gastrointestinal
tract
ABC transporters in, 103, 106t
in autonomic nervous system, 179t
in drug metabolism, 126
ethanol and, 637
opioids and, 497
vectorial transport in, 96, 96f
Intra-arterial administration, 22
Intramuscular administration, 20t, 22
Intraocular pressure
anesthetics and, 1794
in glaucoma, 1775, 1785
regulation of, 1775
Intrathecal administration, 22
Intrauterine device (IUD)
copper, one-year failure rate, 1834t
progestin, 1836
for endometriosis, 1840
one-year failure rate, 1834t
Intravenous administration, 22
characteristics of, 20t
Intravenous immunoglobulin(s)
(IVIG), 1024
contraindications to, 1827
in dermatology, 1827
mechanism of action of, 1827
Intravenous regional anesthesia, 577
Intrinsic coagulation pathway, 853
INTRON A (interferon α-2b), 1596t, 1818
Intron/exon boundary polymorphism,
155t
Intronic polymorphism, 155t
Invention
cost of, 14f
definition of, 3
INVERSINE (mecamylamine
hydrochloride), 272
Investigational New Drug (IND)
application, 7
INVIRASE (saquinavir), 1626t
In vitro fertilization (IVF), ovarian
stimulation in, 1843, 1844f
Involuntary nervous system. See
Autonomic nervous system
(ANS)
Iodide, 1152–1154
Iodine
radioactive, 1154–1157
thyroid function and, 1137–1138
Iodine tincture, 1153t
Iodine-131 tositumomab, 1746t, 1749
dosage and administration of, 1747t
toxicity of, 1747t
Iodochlorhydroxyquin (clioquinol),
1153t
Iodochlorhydroxyquin cream, 1153t
Iodoform gauze, 1153t
IODO-NIACIN (niacinamide
hydroiodide/potassium
iodide), 1153t
Iodophenpropit, 925
Iodoquinol, 1153t
Iodoquinol cream, 1153t
Iohexol, 1153t
Ion channels, 53t, 58–60
and cardiac electrophysiology,
815–816, 816f, 817f
in central nervous system, 367–371
Ionic inhibitors, 1151–1152
Ionic milieu, 51
Iontophoretic administration, of
analgesics, 518
IOP. See Intraocular pressure
Iopanoic acid, 1153t
Iothalamate, 1153t
Ipodate, 1153t
Ipratropium, 226–227, 227f,
230–231
IPRIVASK (desirudin), 859
IPSP. See Inhibitory postsynaptic
potential (IPSP)
IQUIX (levofloxacin), 1781t
Irbesartan, 738
as antihypertensive agent, 774t,
785–786
pharmacokinetics of, 1852t
structure of, 737f